SCHEMBL4354956

SCHEMBL4354956

O=C1N=C(N2CCOCC2)S/C1=C\c1cnc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.62
MEN1 O00255 5/20 0.62
MAPT P10636 12/20 0.57
RAB9A P51151 4/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
NPC1 O15118 2/20 0.57
ALDH1A1 P00352 9/20 0.56
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.52
HCRTR1 O43613 1/20 0.52
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 3/20 0.50
POLB P06746 3/20 0.50
HTT P42858 2/20 0.50
DCTPP1 Q9H773 1/20 0.49
PSMD14 O00487 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354957 1.00 KMT2A (0.62) KMT2AMEN1MAPTRAB9ACYP1A2
SCHEMBL4351561 0.89 DCTPP1 (0.63) KMT2AMEN1MAPTRAB9ACYP1A2
SCHEMBL4351562 0.89 DCTPP1 (0.63) KMT2AMEN1MAPTRAB9ACYP1A2
SCHEMBL4352431 0.84 GRIN1 (0.67) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4352435 0.84 GRIN1 (0.67) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4354258 0.81 ALDH1A1 (0.78) KMT2AMEN1MAPTRAB9ACYP1A2
SCHEMBL4354253 0.81 ALDH1A1 (0.78) KMT2AMEN1MAPTRAB9ACYP1A2
SCHEMBL4357230 0.81 ENPP2 (0.48) KMT2AMEN1MAPTALDH1A1HTT
SCHEMBL4357226 0.81 ENPP2 (0.48) KMT2AMEN1MAPTALDH1A1HTT
Bromide SCHEMBL4352446 0.81 ALDH1A1 (0.76) KMT2AMEN1MAPTRAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 KMT2A 3923/4885MEN1 1725/4885MAPT 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.